Congratulations to Onyx Pharmaceuticals!

Accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection

Anti-cancer drug gets acellerated FDA approval

Congratulations to Onyx Pharmaceuticals on the accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection, a proteasome inhibitor for the treatment of patients with multiple myeloma. Read the official press release.

For some analysts take on business ramifications, see:

http://www.onclive.com/web-exclusives/FDA-Approves-Carfilzomib-for-Relapsed-Multiple-Myeloma,

http://www.fiercepharma.com/story/onyx-staffs-kyprolis-assault-myeloma-market/2012-07-23,

http://www.thepharmaletter.com/file/115113/onyx-soars-as-fda-approves-kyprolis-for-multiple-myeloma.html,

Disclaimer:  CDD’s Barry Bunin was on one of the early patents for carfilzomib:  Smyth, M. S.; Laidig, G. J; Borchardt, R. T.; Bunin, B. A.; Crews, C. M.; Musser, J. H.; Schneekloth, J. S.; Chabala, J. C.  Compounds for Enzyme Inhibition.  Patent No. US 2005/0245434 A1; issued 3 Nov 2005 (Proteolix, Inc).  Proteolix was acquired by Onyx Pharmaceuticals: http://www.onyx-pharm.com/news/onyx-pharmaceuticals-to-acquire-proteolix-inc


This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!

CDD Vault: Drug Discovery Informatics your whole project team will embrace!

Translated with Google Translate